StemCell Institute Inc.

TSE:7096 Stock Report

Market Cap: JP¥15.6b

StemCell Institute Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Takafumi Shimizu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure8.7yrs
CEO ownership0.5%
Management average tenureno data
Board average tenure4.7yrs

Recent management updates

Recent updates

StemCell Institute Inc. (TSE:7096) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

Dec 06
StemCell Institute Inc. (TSE:7096) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

StemCell Institute's (TSE:7096) Returns On Capital Not Reflecting Well On The Business

Nov 14
StemCell Institute's (TSE:7096) Returns On Capital Not Reflecting Well On The Business

StemCell Institute Inc. (TSE:7096) Stocks Pounded By 26% But Not Lagging Market On Growth Or Pricing

Aug 05
StemCell Institute Inc. (TSE:7096) Stocks Pounded By 26% But Not Lagging Market On Growth Or Pricing

CEO

Takafumi Shimizu (51 yo)

8.7yrs

Tenure

Mr. Takafumi Shimizu serves as the President and Representative Director at StemCell Institute Inc. since June 2016 and serves as its Chairman.


Board Members

NamePositionTenureCompensationOwnership
Takafumi Shimizu
Chairman & President8.7yrsno data0.50%
¥ 78.4m
Kimihide Ando
Independent Outside Director4.7yrsno data0.039%
¥ 6.1m
Yoshito Fujikawa
Independent Outside Audit & Supervisory Board Member6yrsno datano data
Tomoo Yamada
Independent Outside Director6yrsno data0.0039%
¥ 609.4k
Ken Nagae
Independent Outside Audit & Supervisory Board Chairman1.7yrsno datano data
Yumi Okubo
Independent Outside Director1.7yrsno datano data
Yuko Morisawa
Independent Outside Audit & Supervisory Board Member1.7yrsno datano data

4.7yrs

Average Tenure

54yo

Average Age

Experienced Board: 7096's board of directors are considered experienced (4.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/12 03:18
End of Day Share Price 2025/02/12 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

StemCell Institute Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Masatoshi NagataIchiyoshi Research Institute Inc.
null nullStorm Research Limited